|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CYB5R2 |
Gene summary for CYB5R2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CYB5R2 | Gene ID | 51700 |
| Gene name | cytochrome b5 reductase 2 | |
| Gene Alias | B5R.2 | |
| Cytomap | 11p15.4 | |
| Gene Type | protein-coding | GO ID | GO:0006629 | UniProtAcc | A8K237 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 51700 | CYB5R2 | LZE7T | Human | Esophagus | ESCC | 4.01e-05 | 4.07e-01 | 0.0667 |
| 51700 | CYB5R2 | LZE22T | Human | Esophagus | ESCC | 2.34e-03 | 3.09e-01 | 0.068 |
| 51700 | CYB5R2 | P2T-E | Human | Esophagus | ESCC | 6.45e-09 | 1.95e-01 | 0.1177 |
| 51700 | CYB5R2 | P4T-E | Human | Esophagus | ESCC | 1.26e-10 | 3.61e-01 | 0.1323 |
| 51700 | CYB5R2 | P5T-E | Human | Esophagus | ESCC | 4.57e-08 | 2.46e-01 | 0.1327 |
| 51700 | CYB5R2 | P9T-E | Human | Esophagus | ESCC | 1.50e-15 | 4.88e-01 | 0.1131 |
| 51700 | CYB5R2 | P10T-E | Human | Esophagus | ESCC | 4.26e-39 | 7.92e-01 | 0.116 |
| 51700 | CYB5R2 | P11T-E | Human | Esophagus | ESCC | 1.71e-02 | 1.83e-01 | 0.1426 |
| 51700 | CYB5R2 | P12T-E | Human | Esophagus | ESCC | 3.23e-17 | 4.08e-01 | 0.1122 |
| 51700 | CYB5R2 | P15T-E | Human | Esophagus | ESCC | 5.94e-13 | 4.81e-01 | 0.1149 |
| 51700 | CYB5R2 | P16T-E | Human | Esophagus | ESCC | 1.17e-06 | 2.19e-01 | 0.1153 |
| 51700 | CYB5R2 | P17T-E | Human | Esophagus | ESCC | 6.28e-06 | 2.60e-01 | 0.1278 |
| 51700 | CYB5R2 | P19T-E | Human | Esophagus | ESCC | 2.77e-03 | 3.80e-01 | 0.1662 |
| 51700 | CYB5R2 | P20T-E | Human | Esophagus | ESCC | 5.86e-09 | 2.65e-01 | 0.1124 |
| 51700 | CYB5R2 | P21T-E | Human | Esophagus | ESCC | 6.74e-27 | 6.26e-01 | 0.1617 |
| 51700 | CYB5R2 | P24T-E | Human | Esophagus | ESCC | 1.12e-12 | 4.06e-01 | 0.1287 |
| 51700 | CYB5R2 | P26T-E | Human | Esophagus | ESCC | 3.97e-12 | 3.83e-01 | 0.1276 |
| 51700 | CYB5R2 | P27T-E | Human | Esophagus | ESCC | 2.23e-04 | 1.90e-01 | 0.1055 |
| 51700 | CYB5R2 | P28T-E | Human | Esophagus | ESCC | 5.57e-30 | 8.10e-01 | 0.1149 |
| 51700 | CYB5R2 | P30T-E | Human | Esophagus | ESCC | 1.56e-12 | 4.18e-01 | 0.137 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00161263 | Esophagus | ESCC | sterol biosynthetic process | 46/8552 | 64/18723 | 1.91e-05 | 1.67e-04 | 46 |
| GO:00066946 | Esophagus | ESCC | steroid biosynthetic process | 98/8552 | 173/18723 | 2.34e-03 | 1.03e-02 | 98 |
| GO:00161254 | Esophagus | ESCC | sterol metabolic process | 86/8552 | 152/18723 | 4.37e-03 | 1.73e-02 | 86 |
| GO:19016174 | Esophagus | ESCC | organic hydroxy compound biosynthetic process | 128/8552 | 237/18723 | 5.86e-03 | 2.16e-02 | 128 |
| GO:00161262 | Oral cavity | OSCC | sterol biosynthetic process | 39/7305 | 64/18723 | 3.12e-04 | 1.94e-03 | 39 |
| GO:00066945 | Oral cavity | OSCC | steroid biosynthetic process | 89/7305 | 173/18723 | 5.77e-04 | 3.30e-03 | 89 |
| GO:19016173 | Oral cavity | OSCC | organic hydroxy compound biosynthetic process | 115/7305 | 237/18723 | 1.73e-03 | 8.18e-03 | 115 |
| GO:00161253 | Oral cavity | OSCC | sterol metabolic process | 77/7305 | 152/18723 | 2.26e-03 | 1.00e-02 | 77 |
| GO:00082024 | Oral cavity | OSCC | steroid metabolic process | 146/7305 | 319/18723 | 7.78e-03 | 2.85e-02 | 146 |
| GO:001612611 | Oral cavity | LP | sterol biosynthetic process | 27/4623 | 64/18723 | 1.57e-03 | 1.21e-02 | 27 |
| GO:000669412 | Oral cavity | LP | steroid biosynthetic process | 58/4623 | 173/18723 | 5.44e-03 | 3.31e-02 | 58 |
| GO:001612511 | Oral cavity | LP | sterol metabolic process | 51/4623 | 152/18723 | 8.57e-03 | 4.63e-02 | 51 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa005202 | Esophagus | ESCC | Amino sugar and nucleotide sugar metabolism | 35/4205 | 49/8465 | 1.60e-03 | 4.88e-03 | 2.50e-03 | 35 |
| hsa0052011 | Esophagus | ESCC | Amino sugar and nucleotide sugar metabolism | 35/4205 | 49/8465 | 1.60e-03 | 4.88e-03 | 2.50e-03 | 35 |
| hsa00520 | Oral cavity | OSCC | Amino sugar and nucleotide sugar metabolism | 34/3704 | 49/8465 | 2.48e-04 | 8.08e-04 | 4.11e-04 | 34 |
| hsa005201 | Oral cavity | OSCC | Amino sugar and nucleotide sugar metabolism | 34/3704 | 49/8465 | 2.48e-04 | 8.08e-04 | 4.11e-04 | 34 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CYB5R2 | SNV | Missense_Mutation | rs777770734 | c.56N>T | p.Pro19Leu | p.P19L | Q6BCY4 | protein_coding | tolerated(0.18) | benign(0.013) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CYB5R2 | SNV | Missense_Mutation | rs779602178 | c.722C>T | p.Ala241Val | p.A241V | Q6BCY4 | protein_coding | deleterious(0.03) | benign(0.027) | TCGA-AX-A0J1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CYB5R2 | SNV | Missense_Mutation | novel | c.339N>T | p.Glu113Asp | p.E113D | Q6BCY4 | protein_coding | tolerated(1) | benign(0) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
| CYB5R2 | SNV | Missense_Mutation | novel | c.647N>T | p.Arg216Met | p.R216M | Q6BCY4 | protein_coding | deleterious(0) | possibly_damaging(0.885) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CYB5R2 | SNV | Missense_Mutation | rs75978231 | c.691N>A | p.Asp231Asn | p.D231N | Q6BCY4 | protein_coding | tolerated(0.13) | benign(0.052) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CYB5R2 | SNV | Missense_Mutation | novel | c.431N>C | p.Lys144Thr | p.K144T | Q6BCY4 | protein_coding | tolerated(0.59) | benign(0.001) | TCGA-EY-A1GI-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CYB5R2 | insertion | Frame_Shift_Ins | novel | c.432_433dupAA | p.Thr145LysfsTer9 | p.T145Kfs*9 | Q6BCY4 | protein_coding | TCGA-A5-A0GG-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| CYB5R2 | insertion | Nonsense_Mutation | novel | c.95_96insTTTTTCCATGTGAGT | p.Thr32_Arg33insPheSerMetTerVal | p.T32_R33insFSM*V | Q6BCY4 | protein_coding | TCGA-AX-A06J-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | SD | ||
| CYB5R2 | insertion | Frame_Shift_Ins | novel | c.433_434insA | p.Thr145AsnfsTer31 | p.T145Nfs*31 | Q6BCY4 | protein_coding | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD | ||
| CYB5R2 | insertion | Frame_Shift_Ins | novel | c.272_273insA | p.Asn91LysfsTer8 | p.N91Kfs*8 | Q6BCY4 | protein_coding | TCGA-B5-A11U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 51700 | CYB5R2 | DRUGGABLE GENOME | primaquine | PRIMAQUINE | ||
| 51700 | CYB5R2 | DRUGGABLE GENOME | metoclopramide | METOCLOPRAMIDE | ||
| 51700 | CYB5R2 | DRUGGABLE GENOME | isosorbide dinitrate | |||
| 51700 | CYB5R2 | DRUGGABLE GENOME | isosorbide mononitrate | |||
| 51700 | CYB5R2 | DRUGGABLE GENOME | rasburicase | RASBURICASE |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |